HeySPKimmelmanJ. The questionable use of unequal allocation in confirmatory trials. Neurology2014; 82: 77–79.
2.
HeySPKimmelmanJ. Ethics, error, and initial trials of efficacy. Sci Transl Med2013; 5: 184fs16.
3.
HayMThomasDWCraigheadJL. Clinical development success rates for investigational drugs. Nat Biotechnol2014; 32: 40–51.
4.
KolaILandisJ. Can the pharmaceutical industry reduce attrition rates?Nat Rev Drug Discov2004; 3: 711–715.
5.
EmanuelEJWendlerDGradyC. What makes clinical research ethical?JAMA2000; 283: 2701–2711.
6.
HarmonA. New drugs stir debate on rules of clinical trials. The New York Times, 18September2010, p. A1.
7.
McArthurGAChapmanPBRobertC. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV 600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol2014; 15: 323–332.
